Recruitment Retention & Diversity: The Evolution Of Patient Engagement In Clinical Trials
Recruitment Retention & Diversity: The Evolution Of Patient Engagement In Clinical Trials
Sponsored by:
Sponsored by:
More from Clinical Trials
• By
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
• By
One Phase III trial hits but a second study misses by a mile.
• By
Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.
• By
Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback
More from R&D
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Sponsored by:
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.
Sponsored by:
Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.